{
  "id": 1234608,
  "title": "Immunome director Isaac Barchas sells $940,453 in common stock",
  "url": "https://urgent.news/2026/08/16/immunome-director-isaac-barchas-sells-940-453-in-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-16T08:01:24.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/immunome-director-isaac-barchas-sells-940453-in-common-stock-93CH-4861943"
  },
  "original_language": "en",
  "account": "Immunome Inc.'s Director, Isaac Barchas, sold shares of the company's common stock in two transactions during early August 2026, totaling $940,453. The sales took place on August 6 and August 7 at an average price of $26.06 per share, as noted by a recent SEC filing. The transactions occurred while the stock price hovered near its 52-week high of $28.62, following a 165% increase over the past year. The stock is currently valued at $27.20, despite its strong performance. On August 6, Barchas sold 20,840 shares between $26.00 and $26.3318 per share, while on August 7, he sold an additional 15,248 shares at prices ranging from $26.00 to $26.25 per share. These trades were executed under a Rule 10b5-1 trading plan initiated by ABHMC II LLC, where Barchas serves as a managing member. The indirect beneficial ownership of Immunome common stock held by ABHMC, over which Barchas has investment power, stands at 72,416 shares following the transactions. ABHMC has disclaimed beneficial ownership of these shares, except for Barchas' financial interest. The company recently announced the FDA's acceptance of its New Drug Application for varegacestat, a treatment for desmoid tumors. The FDA has set a target action date of April 28, 2027, for this application. H.C. Wainwright has also reiterated a Buy rating for Immunome, maintaining a $40.00 price target. The company has also initiated Phase 1 trials for IM-3050 and IM-1617, aiming to assess safety and preliminary anti-tumor activity in solid tumors.",
  "summary": null,
  "key_points": [
    "Director Isaac Barchas sold $940,453 worth of Immunome stock",
    "Sales occurred on August 6 and 7 at $26.06 per share average",
    "ABHMC II LLC initiated Rule 10b5-1 trading plan for transactions"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}